Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.06
BIOS's Cash to Debt is ranked lower than
83% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. BIOS: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
BIOS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.06

Equity to Asset 0.24
BIOS's Equity to Asset is ranked lower than
77% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. BIOS: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
BIOS' s 10-Year Equity to Asset Range
Min: 0.24   Max: 0.75
Current: 0.24

0.24
0.75
F-Score: 2
Z-Score: 0.60
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -8.41
BIOS's Operating margin (%) is ranked lower than
87% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 7.51 vs. BIOS: -8.41 )
Ranked among companies with meaningful Operating margin (%) only.
BIOS' s 10-Year Operating margin (%) Range
Min: -11.69   Max: 4.61
Current: -8.41

-11.69
4.61
Net-margin (%) -14.09
BIOS's Net-margin (%) is ranked lower than
90% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 3.31 vs. BIOS: -14.09 )
Ranked among companies with meaningful Net-margin (%) only.
BIOS' s 10-Year Net-margin (%) Range
Min: -16.05   Max: 9.77
Current: -14.09

-16.05
9.77
ROE (%) -52.64
BIOS's ROE (%) is ranked lower than
95% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 9.41 vs. BIOS: -52.64 )
Ranked among companies with meaningful ROE (%) only.
BIOS' s 10-Year ROE (%) Range
Min: -57.57   Max: 43.05
Current: -52.64

-57.57
43.05
ROA (%) -16.44
BIOS's ROA (%) is ranked lower than
91% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 3.44 vs. BIOS: -16.44 )
Ranked among companies with meaningful ROA (%) only.
BIOS' s 10-Year ROA (%) Range
Min: -27.23   Max: 20.26
Current: -16.44

-27.23
20.26
ROC (Joel Greenblatt) (%) -72.85
BIOS's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 207 Companies
in the Global Medical Care industry.

( Industry Median: 14.26 vs. BIOS: -72.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -902.86   Max: 227.09
Current: -72.85

-902.86
227.09
Revenue Growth (3Y)(%) 12.20
BIOS's Revenue Growth (3Y)(%) is ranked higher than
74% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. BIOS: 12.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -35   Max: 15.9
Current: 12.2

-35
15.9
EPS Growth (3Y)(%) 493.40
BIOS's EPS Growth (3Y)(%) is ranked higher than
99% of the 111 Companies
in the Global Medical Care industry.

( Industry Median: 9.00 vs. BIOS: 493.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -82.7   Max: 493.4
Current: 493.4

-82.7
493.4
» BIOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BIOS Guru Trades in Q2 2014

Mario Gabelli 1,440,840 sh (+75.98%)
Mario Gabelli 2,255,552 sh (+175.48%)
Pioneer Investments 280,320 sh (unchged)
Steven Cohen 416,500 sh (unchged)
Ron Baron 144,010 sh (unchged)
» More
Q3 2014

BIOS Guru Trades in Q3 2014

Ron Baron 281,300 sh (+95.33%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 2,593,352 sh (unchged)
Mario Gabelli 2,593,352 sh (unchged)
Mario Gabelli 1,431,426 sh (-0.65%)
Steven Cohen 92,100 sh (-77.89%)
» More
Q4 2014

BIOS Guru Trades in Q4 2014

Ron Baron 345,500 sh (+22.82%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 4,171,782 sh (unchged)
Mario Gabelli 4,171,782 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 1,178,601 sh (-17.66%)
» More
Q1 2015

BIOS Guru Trades in Q1 2015

Mario Gabelli 1,300,981 sh (+10.38%)
Ron Baron 372,500 sh (+7.81%)
Mario Gabelli 7,666,300 sh (+14.97%)
Pioneer Investments 280,320 sh (unchged)
Louis Moore Bacon 130,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 33.22
BIOS's Forward P/E is ranked lower than
90% of the 174 Companies
in the Global Medical Care industry.

( Industry Median: 19.08 vs. BIOS: 33.22 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.20
BIOS's P/B is ranked higher than
89% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 3.00 vs. BIOS: 1.20 )
Ranked among companies with meaningful P/B only.
BIOS' s 10-Year P/B Range
Min: 0.3   Max: 3.1
Current: 1.2

0.3
3.1
P/S 0.20
BIOS's P/S is ranked higher than
98% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. BIOS: 0.20 )
Ranked among companies with meaningful P/S only.
BIOS' s 10-Year P/S Range
Min: 0.04   Max: 1.89
Current: 0.2

0.04
1.89
Current Ratio 1.46
BIOS's Current Ratio is ranked higher than
57% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 1.35 vs. BIOS: 1.46 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s 10-Year Current Ratio Range
Min: 0.86   Max: 2.76
Current: 1.46

0.86
2.76
Quick Ratio 1.17
BIOS's Quick Ratio is ranked lower than
53% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 1.22 vs. BIOS: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s 10-Year Quick Ratio Range
Min: 0.79   Max: 2.5
Current: 1.17

0.79
2.5
Days Inventory 17.87
BIOS's Days Inventory is ranked higher than
50% of the 150 Companies
in the Global Medical Care industry.

( Industry Median: 17.87 vs. BIOS: 17.87 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s 10-Year Days Inventory Range
Min: 0.52   Max: 80.5
Current: 17.87

0.52
80.5
Days Sales Outstanding 49.56
BIOS's Days Sales Outstanding is ranked lower than
57% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 46.90 vs. BIOS: 49.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s 10-Year Days Sales Outstanding Range
Min: 23.97   Max: 164.17
Current: 49.56

23.97
164.17

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
BIOS's Price/Median PS Value is ranked higher than
80% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 1.20 vs. BIOS: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOS' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.48
Current: 1

0.21
5.48
Earnings Yield (Greenblatt) -13.50
BIOS's Earnings Yield (Greenblatt) is ranked lower than
92% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 4.30 vs. BIOS: -13.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
BIOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -13.5   Max: 9.5
Current: -13.5

-13.5
9.5
Forward Rate of Return (Yacktman) -86.95
BIOS's Forward Rate of Return (Yacktman) is ranked lower than
100% of the 104 Companies
in the Global Medical Care industry.

( Industry Median: 10.63 vs. BIOS: -86.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
BIOS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -88.6   Max: 51.5
Current: -86.95

-88.6
51.5

Business Description

Industry: Health Care Providers » Medical Care
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:MM6.Germany,
BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The Company operates in three reportable segments: Infusion Services, Home Health Services, and Pharmacy Benefit Management Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment products and services. Infusion Services include the dispensing and administering of infusion-based drugs, which requires additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home Health Services provides services that include the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home. The integrated Pharmacy Benefit Management Services' operating and reportable segment consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. The discount card allows an individual to receive prescription medications at a discounted price compared to the retail price. The Company has approximately 250 sales and marketing representatives and over 1,000 payor relationships including MCOs, Medicare Part D pharmacy networks, other government programs such as Medicare and Medicaid and other Third Party Payors. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusio
» More Articles for NAS:BIOS

Headlines

Articles On GuruFocus.com
5-year lows: Elizabeth Arden Inc, Systemax Inc, BioScrip Inc, and Thompson Creek Metals Co Inc. May 26 2015 
5-year lows: Resource Capital Corp, Dynex Capital Inc, BioScrip Inc, and Kemet Corp. May 10 2015 
Two Gurus Hold Stakes in Embattled BioScrip Apr 07 2015 
A Look at Mario Gabelli's Latest Stake Increases Apr 01 2015 
Mario Gabelli Ups Stake in BioScript, But Value of Stock Declines Mar 18 2015 
A Look at Mario Gabelli's New Added Positions Feb 04 2015 
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014 
Soros and Gabelli Top Guru Real Time Picks of the Week Aug 08 2014 
Gurus' Real Time Stock Picks of the Week May 09 2014 
Morning Coffee: Real-Time Picks May 07 2014 

More From Other Websites
BIOSCRIP, INC. Files SEC form 8-K, Regulation FD Disclosure May 29 2015
BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 27 2015
BioScrip's Loss, Margins Worry; Infusion Services Offers Hope - Analyst Blog May 19 2015
13F Watch: Krevlin's Glenhill Advisors Buys Pier 1, Nexstar; Slashes American Airlines, Jamba May 18 2015
BIOSCRIP, INC. Financials May 15 2015
BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 14 2015
BioScrip (BIOS) Q1 Loss Wider than Expected; Revenues Beat - Analyst Blog May 12 2015
10-Q for BioScrip, Inc. May 11 2015
BioScrip Announces Proposal to Commence Exchange Offer May 11 2015
BioScrip Inc Earnings Call scheduled for 8:30 am ET today May 08 2015
BIOSCRIP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 08 2015
Thursday's After-Hours Movers: NeoPhotonics, Quality Distribution And More May 07 2015
BioScrip Reports First Quarter 2015 Financial Results May 07 2015
Scott+Scott, Attorneys at Law, LLP Announces Investigation of BioScrip, Inc. May 07 2015
Q1 2015 BioScrip Inc Earnings Release - After Market Close May 07 2015
Express Scripts unit to pay $60 mln over Novartis kickbacks, US says May 01 2015
Express Scripts unit to pay $45 million to U.S. over Novartis kickback scheme May 01 2015
BIOSCRIP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 01 2015
BioScrip To Host 2015 First Quarter Results Call Apr 30 2015
BioScrip To Host 2015 First Quarter Results Call Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK